title: Oropharyngeal candidiasis with dry-powdered fluticasone propionate: 500 microg/day versus 200 microg/day.
abstract: We aimed to determine the frequency of oropharyngeal candidiasis and its clinical correlates in the asthmatic patients who use fluticasone propionate (FP) as a dry powdered inhaler. We selected four groups of patients: 62 asthmatic patients who were taking 200 microg/d FP, 122 asthmatics who were taking 500 microg/d FP, 50 asthmatic patients who had not been on inhaled corticosteroid (ICS) treatment and 40 normal non-asthmatic subjects. The frequency of positive swabs for Candida colonization was higher in 500 microg/d FP group than asthmatics without ICS use (chi2 = 6.8, p < 0.05) and normal controls (chi2 = 4.9, p < 0.05), whereas it wasn't different in the 200 microg/day FP group when compared to controls. When we considered patients who used ICS, the most effective variables affecting the occurrence of Candida colonization were washing of the throat by the patients (OR = 9.4, 95 % Confidence Interval [CI] = 3.9-22.7, p < 0.0001) and duration of ICS use more than 12 months (OR = 2.5, 95 % CI = 1.1-2.6, p < 0.05). The present study showed that in the patients who use ICS, the most important determinants on colonization were not washing the throat regularly and duration of ICS use for more than 12 months.
authors.affiliation: Department of Chest Diseases, Osmangazi University, Faculty of Medicine, Eskisehir, Turkey. heylul2002@yahoo.com
authors.forename: E
authors.initials: E
authors.lastname: Kurt
authors.forename: H
authors.initials: H
authors.lastname: Yildirim
authors.forename: N
authors.initials: N
authors.lastname: Kiraz
authors.forename: A
authors.initials: A
authors.lastname: Orman
authors.forename: M
authors.initials: M
authors.lastname: Metintas
authors.forename: Y
authors.initials: Y
authors.lastname: Akgun
authors.forename: S
authors.initials: S
authors.lastname: Erginel
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy; D002180:Candidiasis, Oral / Q000209:etiology* / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D008875:Middle Aged; D010612:Pharyngitis / Q000209:etiology* / Q000382:microbiology / Q000517:prevention & control; D011208:Powders; D007507:Therapeutic Irrigation
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D011208:Powders; D000068298:Fluticasone